Journal of Clinical Oncology, Vol 1, 171-178, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Stage II nonseminomatous testicular cancer: a 10-year experience

NJ Vogelzang, EE Fraley, PH Lange, J Torkelson, S Levitt and BJ Kennedy

Between 1970 and 1980, 82 patients with pathologic stage II nonseminomatous germ cell testicular carcinoma were treated at the University of Minnesota. Of the 30 patients treated with a retroperitoneal lymph node dissection, 22 (77%) relapsed. Of the 18 patients treated with retroperitoneal lymph node dissection and adjuvant radiotherapy, 12 (63%) relapsed. Sixteen patients received adjuvant chemotherapy before 1976, and 14 (87.5%) relapsed. After 1976, 18 patients received adjuvant chemotherapy (11 with cisplatin) and 2 (11%) have relapsed. No patient treated with cisplatin-based adjuvant chemotherapy has relapsed. The toxicity has been modest. Cisplatin- based chemotherapy is an effective and a safe adjuvant therapy for stage II nonseminomatous germ cell testicular carcinoma.

This article has been cited by other articles:

				A. J. Stephenson, G. J. Bosl, R. J. Motzer, M. W. Kattan, J. Stasi, D. F. Bajorin, and J. Sheinfeld Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome J. Clin. Oncol., April 20, 2005; 23(12): 2781 - 2788. [Abstract] [Full Text] [PDF]

				F. Rabbani, J. Sheinfeld, H. Farivar-Mohseni, A. Leon, M. J. Rentzepis, V. E. Reuter, H. W. Herr, J. A. McCaffrey, R. J. Motzer, D. F. Bajorin, et al. Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse J. Clin. Oncol., April 1, 2001; 19(7): 2020 - 2025. [Abstract] [Full Text] [PDF]